Stopping SOAT1 sparks an immune attack on liver cancer: a metabolic-immune axis in hepatocellular carcinoma

Abstract Ma et al. identified sterol O-acyltransferase 1 (SOAT1) as a key metabolic-immune node in hepatocellular carcinoma (HCC). These authors revealed that SOAT1 loss induced ROS-driven ER stress that activates IKK β -NF- κ B signaling and up-regulates the chemokines CXCL16, CXCL12, and CX3CL1, which reshape the tumor microenvironment to favor antigen presentation and T-cell cytotoxicity. Consequently, SOAT1 inhibition synergizes with anti-PD-1 therapy, underscoring SOAT1 as a tractable target to combine metabolic disruption with immune activation in HCC. This study establishes SOAT1 as a key metabolic-immune node that may potentially impact the field of HCC treatment. SOAT1 inhibitors have the potential to act synergistically with additional immune checkpoint inhibitors beyond anti-PD-1, including anti-CTLA-4, anti-LAG-3, or anti-TIM-3 antibodies, as the metabolic reprogramming resulting from SOAT1 inhibition significantly modifies the tumor microenvironment. Moreover, SOAT1 inhibition may be integrated with locoregional therapies frequently employed in the management of hepatocellular carcinoma, such as trans arterial chemoembolization or radioembolization. Finally, SOAT1 expression levels or lipid metabolic signatures may function as biomarkers for patient stratification in forthcoming clinical trials, facilitating the development of more tailored combination therapy strategies. However, assessment of drug toxicity and careful selection of patients are potential challenges that may impede timely clinical implementation.